Treatment News : Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2014

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 31, 2014

Daclatasvir/Olysio Combo Effectively Treats Hep C Genotype 1b

CROI 2014A combination of low-dose daclatasvir and Olysio (simeprevir) cured a relatively high proportion of people with genotype 1b of hepatitis C virus (HCV), but just two thirds of a small group of genotype 1a’s. Findings from the LEAGUE-1 trial were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and reported by aidsmap.

The safety and efficacy study included 147 participants with genotype 1b, including 104 treatment-naive participants and 43 prior null responders. Another part of the study included 21 people with genotype 1a.

Those with genotype 1b randomly received 30 milligrams a day of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir and 150 mg a day of Janssen’s Olysio, with or without ribavirin. Twelve weeks into treatment they were randomized again, this time either to stop therapy or to continue for an additional 12 weeks.

All of the participants with genotype 1a took daclatasvir, Olysio and ribavirin for 24 weeks.

Eighty-one percent of the treatment-naive 1b’s who received 12 weeks of two-drug treatment and 89 percent who received 24 weeks achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). The cure rates for those who received three drugs were 75 percent in the 12-week group and 74 percent in the 24-week group.

Among the null responder participants with genotype 1b, 65 percent of those who took the two-drug regimen and 95 percent who took the three-drug cocktail achieved an SVR12.

Sixty-seven percent of the participants with genotype 1a were cured. The four people, comprising the remaining 33 percent, who were not cured experienced viral breakthrough.

Daclatasvir and Olysio proved generally safe and well tolerated, with 9 percent of those taking the two-drug regimen and 4 percent who also took ribavirin experiencing serious side effects. A respective 3 and 2 percent stopped treatment as a result of side effects.

To read the aidsmap story, click here.

To watch a webcast of the CROI presentation, click here.

Search: Hepatitis C, virus, hep C, HCV, daclatasvir, Olysio, simeprevir, Bristol-Myers Squibb, LEAGUE-1, Janssen, Conference on Retroviruses and Opportunistic Infections, CROI, aidsmap.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dlw8585
    Fort Lauderdale
    Florida


    soy_Ric
    Rochester
    New York


    hollywoodvers1
    Los Angeles
    California


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.